GEHC’s manganese MRI contrast agent advances to phase III

GE HealthCare (GEHC) is moving its investigational manganese-based MRI contrast agent, mangaciclanol, into phase III testing after phase II results from the Lumina trial supported a dose of 0.1 mmol/kg.

In the phase II dose-finding stage, adults with known or highly suspected central nervous system lesions received both mangaciclanol and gadobutrol, a gadolinium-based contrast agent, with blinded independent readers comparing the images side by side. The study, which took place at health centers in the U.S., Europe and Asia, met its primary endpoint, with similar overall diagnostic preference between the two agents, GEHC said.

MRI brain scans comparing pre-dose and post-dose imaging for neurofibromatosis type 2 and metastasis patientsRepresentative pre- and post-mangaciclanol images in patients from the LUMINA Phase 2/3 trial.GE HealthCare

Results also showed that lesion visualization and quantitative imaging findings were also generally similar, and mangaciclanol was well tolerated, with no safety concerns identified, according to the vendor.

Manganese-based agents could provide an alternative to gadolinium-based contrast agents, addressing concerns about retention in the body, supply chain resiliency, and environmental effects, GEHC said. Mangaciclanol has received Fast Track designation from the U.S. Food and Drug Administration (FDA) but is not approved yet by any regulatory authority. 

The company will present preliminary phase II results at the RSNA 2026 meeting in Chicago.

Page 1 of 618
Next Page